Hepion Pharmaceuticals Statistics
Total Valuation
HEPA has a market cap or net worth of $1.81 million. The enterprise value is $2.54 million.
Important Dates
The next estimated earnings date is Tuesday, April 15, 2025, after market close.
| Earnings Date | Apr 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HEPA has 10.62 million shares outstanding. The number of shares has increased by 44.02% in one year.
| Current Share Class | 10.62M |
| Shares Outstanding | 10.62M |
| Shares Change (YoY) | +44.02% |
| Shares Change (QoQ) | +15.86% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 7.56% |
| Float | 8.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | -4.46 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30
| Current Ratio | 1.30 |
| Quick Ratio | 0.55 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -58.74 |
Financial Efficiency
Return on equity (ROE) is -288.27% and return on invested capital (ROIC) is -174.03%.
| Return on Equity (ROE) | -288.27% |
| Return on Assets (ROA) | -110.40% |
| Return on Invested Capital (ROIC) | -174.03% |
| Return on Capital Employed (ROCE) | -2,538.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.03M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.38M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.12% in the last 52 weeks. The beta is 1.65, so HEPA's price volatility has been higher than the market average.
| Beta (5Y) | 1.65 |
| 52-Week Price Change | -93.12% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.73 |
| Relative Strength Index (RSI) | 36.42 |
| Average Volume (20 Days) | 31,356,938 |
Short Selling Information
The latest short interest is 2.71 million, so 25.51% of the outstanding shares have been sold short.
| Short Interest | 2.71M |
| Short Previous Month | 211,627 |
| Short % of Shares Out | 25.51% |
| Short % of Float | 31.89% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.36M |
| Pretax Income | -41.90M |
| Net Income | -22.70M |
| EBITDA | -25.32M |
| EBIT | -25.36M |
| Earnings Per Share (EPS) | -$4.12 |
Full Income StatementBalance Sheet
The company has $1.50 million in cash and $2.22 million in debt, giving a net cash position of -$726,599 or -$0.07 per share.
| Cash & Cash Equivalents | 1.50M |
| Total Debt | 2.22M |
| Net Cash | -726,599 |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | -406,685 |
| Book Value Per Share | -0.30 |
| Working Capital | 814,328 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.07 million and capital expenditures -$348, giving a free cash flow of -$26.07 million.
| Operating Cash Flow | -26.07M |
| Capital Expenditures | -348 |
| Free Cash Flow | -26.07M |
| FCF Per Share | -$2.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |